Advertisement

Leachables and Extractables: From Regulatory Expectations to Laboratory Assessment

  • Michael Jahn
Chapter
Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 38)

Abstract

During manufacturing, storage and administration, a pharmaceutical drug product (DP) formulation and its constituents are in contact with a multitude of polymeric materials. Every such contact leads to leaching of chemicals from the material into the formulation. Health authorities demand from the pharmaceutical manufacturer to control leaching within an extractables/leachables (E/L) assessment as a measure to prevent the patient from undue risk. Such an E/L assessment is structured into different parts. Initially, the manufacturing, storage and administration process is mapped; i.e. all contact materials are listed together with relevant process parameters that might influence leaching. A risk evaluation scores the materials according to their risk. High-risk materials are subjected to laboratory E/L testing. Test conditions, i.e. incubation of materials, should reflect the conditions encountered in the process—too exaggerated incubation conditions leading to excessive extractables profiles that do not correlate with leachables profiles encountered during real contact should be avoided. Analysis of the incubation solutions within screening studies should cover comprehensively the physical–chemical properties of E/L compounds; typical analytical methods are headspace-GC–MS, GC–MS and LC–UV–MS. Quantitative evaluation of analytical data should be performed against analytical evaluation thresholds derived from toxicological safety thresholds. Compounds encountered above the threshold need follow-up activities, e.g. structural identification and toxicological assessment. Special considerations have to be applied and are discussed within this chapter with regard to E/L assessment of drug substance manufacturing materials, the interaction of leachables with process constituents, glass delamination, leaching of silicon oil and leaching from secondary packaging materials, adhesives and printing. In summary, a proper E/L assessment should enable the pharmaceutical manufacturer to choose manufacturing, storage and administration materials that do not pose an undue risk for patients with regard to leaching.

Keywords

Extractables Leachables Risk evaluation Analytical evaluation threshold Glass delamination Silicon oil 

Notes

Acknowledgements

The author would like to acknowledge the countless contributions of Andreas Zerr, Lonza AG, to increasing the knowledge on extractables and leachables.

References

  1. 1.
    Zweifel H. (ed) Plastics additives handbook. Munich: Hanser Publisher. 2000.Google Scholar
  2. 2.
    Food and Drug Administration (FDA). 21 CFR Sec. 211.65, Equipment construction. 2016.Google Scholar
  3. 3.
    Food and Drug Administration (FDA). 21 CFR Sec. 211.94, Drug product containers and closures. 2016.Google Scholar
  4. 4.
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Guidance for industry—container closure systems for packaging human drugs and biologics. 1999.Google Scholar
  5. 5.
    European Medicines Agency, Committee for Medicinal Products for Human and Use (CHMP) and Committee for Medicinal Products for Veterinary Use (CVMP). Guideline on plastic immediate packaging materials. 2005.Google Scholar
  6. 6.
    United States Pharmacopeia. <1663> Assessment of extractables associated with pharmaceutical packaging/delivery systems.Google Scholar
  7. 7.
    United States Pharmacopeia. <1664> Assessment of drug product leachables associated with pharmaceutical packaging delivery systems.Google Scholar
  8. 8.
    International Conference on Harmonization (ICH) M7. Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. 2014.Google Scholar
  9. 9.
    Teasdale A, Jahn M, Bailey S, Feilden A, Taylor G, Corcoran ML, Malick R, Jenke D, Stults CLM, Nagao LM. Controlled extraction studies applied to polyvinyl chloride and polyethylene materials: conclusions from the ELSIE controlled extraction pilot study. AAPS PharmSciTech. 2014;16:664–74.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Sharma B, Bader F, Templeman T, Lisi P, Ryan M, Heavner GA. Technical investigation into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with Eprex®. Eur J Hosp Pharm. 2004;5:86–91.Google Scholar
  11. 11.
    Curry W, Conway L, Goodfield C, Miller K, Mueller RL, Polini E. Reducing the risk of contamination of sterile parenteral products via ready-to-use closure components. AAPS PharmSciTech. 2010;11:1572–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Product Quality Research Institute Leachables and Extractables Working Group. Safety thresholds and best practices for extractables and leachables in orally inhaled and nasal drug products. 2006.Google Scholar
  13. 13.
    American Academy of Pediatrics. Benzyl alcohol: toxic agent in neonatal units. Pediatrics. 1983;72:356–8.Google Scholar
  14. 14.
    International Conference on Harmonization (ICH) Q3D. Guideline for elemental impurities. 2014.Google Scholar
  15. 15.
    Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. Downstream processing of monoclonal antibodies—application of platform approaches. J Chromatogr B. 2007:28–39.CrossRefGoogle Scholar
  16. 16.
    Ding W, Madsen G, Mahajan E, O’Connor S, Wong K. Standardized extractable testing protocol for single-use systems in biomanufacturing. Pharm Eng. 2014;34:1–11.Google Scholar
  17. 17.
    Hammond M, Nunn N, Rogers G, Lee H, Marghitoiu AL, Perez L, Samuel YN, Anderson C, Vandiver M, Kline S. Identification of a leachable compound detrimental to cell growth in single-use bioprocess containers. PDA J Pharm Sci Tech. 2013;67:123–34.CrossRefPubMedGoogle Scholar
  18. 18.
    Bee JS, Nelson SA, Freund E, Carpenter JF, Randolph TW. Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci. 2009;98:3290–301.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Chang JY, Xiao NJ, Zhu M, Zhang J, Hoff E, Russell SJ, Katta V, Shire SJ. Leachables from saline-containing IV bags can alter therapeutic protein properties. Pharm Res. 2010;27:2402–13.CrossRefPubMedGoogle Scholar
  20. 20.
    Ennis RD, Pritchard R, Nakamura C, Coulon M, Yang T, Visor GC, Lee WA. Glass vials for small volume parenterals: influence of drug and manufacturing processes on glass delamination. Pharm Dev Technol. 2001;6:393–405.CrossRefPubMedGoogle Scholar
  21. 21.
    Basu P, Krishnan S, Thirumangalathu R, Randolph TW, Carpenter JF. IgG1 aggregation and particle formation induced by silicone-water interfaces on siliconized borosilicate glass beads: a model for siliconized primary containers. J Pharm Sci. 2013;102:852–65.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  1. 1.Lonza Drug Product Services—Forensic ChemistryBaselSwitzerland

Personalised recommendations